January 9, 2018 / 12:25 PM / Updated 9 minutes ago BRIEF-Axsome Therapeutics Says AXS-02 Independent Data Monitoring Committee Recommends Continuation Of COAST-1 Trial Reuters Staff 1 Min Read 
Jan 9 (Reuters) - Axsome Therapeutics Inc: 
* AXSOME THERAPEUTICS ANNOUNCES AXS-02 INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS CONTINUATION OF COAST-1 TRIAL AND DISCONTINUATION OF CREATE-1 TRIAL 
* AXSOME THERAPEUTICS- IN CREATE-1 TRIAL, AXS-02 TREATMENT RESULTED IN SIGNIFICANT REDUCTION OF SERUM CTX AS COMPARED TO PLACEBO 
* AXSOME THERAPEUTICS- IDMC ALSO REVIEWED AVAILABLE SAFETY INFORMATION IN BOTH STUDIES, CONFIRMED THAT AXS-02 WAS SAFE AND GENERALLY WELL-TOLERATED Source text for Eikon: Further company coverage: